Inhibition of the key necroptosis effectors, RIPK1 or MLKL, could protect MNs against sporadic ALS astroglial toxicity and delay the onset of motor dysfunction (87, 88), therefore suggesting these as potential new therapeutic targets. This evidence concerns the gene MLKL and amyotrophic lateral sclerosis.